The biotech firm reported widening losses as it progresses towards clinical trials. Despite positive regulatory feedback, concerns loom over cash burn and future funding needs.
The biotechnology company has been selected to receive a prestigious award for its research on a drug delivery technology for cancer treatments.
The biotechnology company has formed a Scientific Advisory Board to provide guidance as it prepares to submit a clinical trial application for its lead product, ChemoSeed.
The biotechnology company has announced a non-executive director has purchased shares in the company.
The biotechnology company announces positive feedback from regulators on its plans for a clinical trial of its ChemoSeed drug delivery technology.
The healthcare company has been awarded a grant to advance its drug delivery technology for treating prostate cancer.
Innovative drug delivery company CRISM Therapeutics appoints specialist CRO to advance glioblastoma trial.
Innovative drug delivery company CRISM Therapeutics secures European patent for its ChemoSeed technology, paving the way for further development and commercialization.
The biotechnology firm reported progress in its drug delivery technology development, securing regulatory support and new revenue streams. While still pre-revenue, it's advancing towards clinical trials with a strong cash position.
The biotechnology company will release its interim results and host an investor presentation, but the announcement lacks substantive updates on performance.